Legal and regulatory exposuremixed · 5 filings
“The Company was not subject to any material legal proceedings as of June 30, 2026, and no material legal proceedings are currently pending or threatened.”10-Q · Aug 11, 2026 ↗
Tango Therapeutics, Inc.
TNGX
Market read
Tango Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 12 directly disclosed connections are confirming.
Company+1.6% todayVolume comparison unavailable
Market group0 of 26 activeHigh-Beta Risk-On · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- G&A stock-based compensation rose to $6,923 (thousands) in Q1 2026 from $3,269 in Q1 2025, primarily due to modification of previously issued equity awards.
Invalidation: The isolated read changes if TNGX's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 12 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- G&A stock-based compensation rose to $6,923 (thousands) in Q1 2026 from $3,269 in Q1 2025, primarily due to modification of previously issued equity awards.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods6
Price observations328
Usable filing statements73
Verified relationships11
Evidence supporting the case
- Latest annual revenue changed +48.3% year over year.
- Operating margin changed +167.7 percentage points in the latest annual period.
- Net margin changed +146.9 percentage points in the latest annual period.
Evidence challenging the case
- Diluted shares increased 6.4% in the latest annual period.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 11, 2026
23.766m+38.5%12m+273.6%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$37.0M+383.8%$-0.94—
2022-12-31$24.9M-32.9%$-1.23+41.4%
2023-12-31$36.5M+46.9%$-1.08+7.7%
2024-12-31$42.1M+15.2%$-1.19+15.5%
2025-12-31$62.4M+48.3%$-0.87+6.4%
What management says matters
Persistent and emerging business drivers
Product pipeline and R&Dnegative · 3 filings
“The Company recorded stock-bas ed compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 (in thousands) (in thousa…”10-Q · Aug 11, 2026 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
23.76+1.6% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for TNGX. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for TNGX. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind TNGX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
GILDGilead Sciences, Inc.partnerMay 13, 2026 ▾
“The Company’s revenues are primarily generated through its license and collaboration agreement with Gilead.”
RVMDRevolution Medicines, Inc.partnerMay 13, 2026 ▾
“Clinical Trial Collaboration and Supply Agreements In November 2024, the Company and Revolution Medicines, Inc.”
Depended on by
RVMDRevolution Medicines, Inc.partnerMay 6, 2026 ▾
“Tango Collaboration 80 In November 2024, we entered into a clinical collaboration with Tango Therapeutics, Inc.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TNGX is currently a Follower in the organic co-movement group High-Beta Risk-On. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.